# Tissium

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tissium

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.tissium.com/
- Total disclosed funding: $214M
- Latest round: Series D (Dec 31, 2025)
- Investors on record: 13

## About

Based in France, TISSIUM S.A. specializes in the design and manufacture of innovative tissue reconstruction solutions that address complex medical challenges in surgical procedures. TISSIUM S.A. was founded in 2013 and is headquartered in Paris, France. The company focuses on developing biomorphic programmable polymers for surgical applications. The founders include Christophe Bancel(CEO), Maria Pereira(CIO). In June 2026, Tissium SA raised EUR 30 million in venture debt funding from new investor European Investment Bank. The series D funding was part of a larger EUR 60 million equity and debt funding. TISSIUM specializes in innovative tissue reconstruction solutions through its proprietary biomorphic programmable polymers, designed for complex medical challenges in surgical procedures. Their products enable the reconstruction of damaged tissue, integrating with surrounding tissues to restore natural function across various therapeutic areas such as peripheral nerve, cardiovascular, and gastrointestinal applications. With adaptability for customization according to tissue-specific requirements, TISSIUM's products are utilized in both open surgeries and minimally invasive procedures, catering to hospitals and surgical centers across North America, Europe, and Asia. In the most recent year, TISSIUM reported a revenue of EUR 9,480.673 with an EBITDA loss of EUR 13,937.117. The company plans to utilize the June 2026 funding to support U.S. rollout and clinical trials for new healthcare applications.

## Funding rounds

- Series D, Dec 31, 2025, $35M — Cathay Capital, Merieux Equity Partners
- Series D, May 16, 2023, $54M — Sofinnova Partners, Credit Mutuel Equity, Cathay Capital, Merieux Developpement, ISALT
- Series C, Jul 27, 2021, $59M — Sofinnova Partners, Cathay Capital
- Series B, Feb 2, 2021, $12M — Sofinnova Partners, Credit Mutuel Equity, Omnes Capital, Karista, Bpifrance Investissement, Valquest Partners, BNP Paribas Developpement, M&L Healthcare
- Series B, Jul 29, 2020, $17M — Sofinnova Partners, Credit Mutuel Equity, Omnes Capital, Karista, Bpifrance Investissement, Valquest Partners, BNP Paribas Developpement, M&L Healthcare
- Series A, Sep 11, 2017, $13M — Sofinnova Partners, Credit Mutuel Equity, Omnes Capital, Karista, Bpifrance Investissement
- Series A, May 24, 2016, $13M — Sofinnova Partners, Credit Mutuel Equity, Omnes Capital, Karista, Bpifrance Investissement
- Series A, Nov 23, 2015, $3.2M — Credit Mutuel Equity, Omnes Capital, Karista
- Series A, Dec 3, 2013, $6.9M — Sudinnova, Credit Mutuel Equity, Omnes Capital, Karista

## Investors

- Sudinnova (https://capitalatlas.ai/funds/sudinnova) — Series A
- Credit Mutuel Equity (https://capitalatlas.ai/funds/credit-mutuel-equity) — Series A, Series B, Series D
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series B
- Karista (https://capitalatlas.ai/funds/karista) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B, Series C, Series D
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B
- Valquest Partners — Series B
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series B
- M&L Healthcare — Series B
- Cathay Capital — Series C, Series D
- Merieux Developpement — Series D
- ISALT (https://capitalatlas.ai/funds/isalt) — Series D
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series D